Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data

Detalles Bibliográficos
Autores principales: Shimizu, Hirohito, Kobayashi, Hisanori, Kanbori, Masayoshi, Ishii, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695771/
https://www.ncbi.nlm.nih.gov/pubmed/33030678
http://dx.doi.org/10.1007/s40744-020-00241-4
_version_ 1783615262242635776
author Shimizu, Hirohito
Kobayashi, Hisanori
Kanbori, Masayoshi
Ishii, Yutaka
author_facet Shimizu, Hirohito
Kobayashi, Hisanori
Kanbori, Masayoshi
Ishii, Yutaka
author_sort Shimizu, Hirohito
collection PubMed
description
format Online
Article
Text
id pubmed-7695771
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-76957712020-11-30 Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data Shimizu, Hirohito Kobayashi, Hisanori Kanbori, Masayoshi Ishii, Yutaka Rheumatol Ther Correction Springer Healthcare 2020-10-08 /pmc/articles/PMC7695771/ /pubmed/33030678 http://dx.doi.org/10.1007/s40744-020-00241-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Correction
Shimizu, Hirohito
Kobayashi, Hisanori
Kanbori, Masayoshi
Ishii, Yutaka
Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
title Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
title_full Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
title_fullStr Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
title_full_unstemmed Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
title_short Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
title_sort correction to: effect of golimumab dose escalation in japanese patients with rheumatoid arthritis: post-hoc analysis of post-marketing surveillance data
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695771/
https://www.ncbi.nlm.nih.gov/pubmed/33030678
http://dx.doi.org/10.1007/s40744-020-00241-4
work_keys_str_mv AT shimizuhirohito correctiontoeffectofgolimumabdoseescalationinjapanesepatientswithrheumatoidarthritisposthocanalysisofpostmarketingsurveillancedata
AT kobayashihisanori correctiontoeffectofgolimumabdoseescalationinjapanesepatientswithrheumatoidarthritisposthocanalysisofpostmarketingsurveillancedata
AT kanborimasayoshi correctiontoeffectofgolimumabdoseescalationinjapanesepatientswithrheumatoidarthritisposthocanalysisofpostmarketingsurveillancedata
AT ishiiyutaka correctiontoeffectofgolimumabdoseescalationinjapanesepatientswithrheumatoidarthritisposthocanalysisofpostmarketingsurveillancedata

Ejemplares similares